The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats
Dc. Jewett et al., The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats, BRAIN RES, 909(1-2), 2001, pp. 75-80
Antagonists selective for either kappa- [e.g. nor-binaltorphimine (nor-BNI)
] and mu- (e.g. beta-funaltrexamine) opioid receptors have previously been
shown to reduce both kappa- and mu-opioid-induced feeding. In the present s
tudies, the anorectic effects of GNTI, a newly synthesized antagonist selec
tive for kappa-opioid receptors, were studied in rats. GNTI (0.032-0.32 nmo
l; i.c.v.), administered 15 min prior to food access, reduced feeding induc
ed by the kappa-opioid agonist U50,488 (producing a 70% maximal decrease),
the mu-opioid agonist DAMGO (90% maximal decrease), and 24 h acute food dep
rivation (60% maximal decrease). GNTI did not reduce the orexigenic effects
of butorphanol, an agonist that binds to both kappa- and mu-opioid recepto
rs, and neuropeptide Y (NPY). Taken together, these results suggest that GN
TI is a potent anorectic agent and opioid antagonist in rats. Like nor-BNI,
GNTI reduced feeding induced by both kappa- and mu-opioid agonists. Howeve
r, unlike nor-BNI, GNTI did not alter the orexigenic effects of butorphanol
or NPY. Given the selectivity of GNTI and its effectiveness in several of
the present experiments, its potency, and its short duration of action comp
ared to nor-BNI, GNTI may serve to be a useful tool to study behavioral eff
ects mediated by kappa-opioid receptors. (C) 2001 Published by Elsevier Sci
ence B.V.